SCHEMBL1008043

SCHEMBL1008043

[N][N+]c1ccccn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6750082 0.79
Hydrochloric Acid SCHEMBL8046759 0.79
Fluoride Ion SCHEMBL11599607 0.77
SCHEMBL827664 0.74
SCHEMBL8400154 0.72 KDM4E (0.37)
Dipyridyl SCHEMBL16026539 0.71 KDM4E (0.93)
Dipyridyl SCHEMBL4196776 0.69 KDM4E (0.88)
Dipyridyl SCHEMBL29351528 0.67 KDM4E (1.00)
Dipyridyl SCHEMBL3711450 0.67 KDM4E (1.00)
Dipyridyl SCHEMBL29907716 0.67 KDM4E (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9714244-B2 Substituted pyrido[4,3-d]pyrimidines as Wee-1 inhibitors ALMAC DISCOVERY LIMITED (GB) 2017-07-25 US disclosed
US-9434698-B2 Process for preparing antiviral compounds ABBVIE INC. (US) 2016-09-06 US disclosed
US-20160158377-A1 BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same ABBVIE INC. (US) 2016-06-09 US disclosed
US-9345702-B2 Methods of treatment using selective Bcl-2 inhibitors ABBVIE INC. (US) 2016-05-24 US disclosed
US-20160060258-A1 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS ALMAC DISCOVERY LIMITED (GB) 2016-03-03 US disclosed
US-9095590-B2 Anti-infective agents and uses thereof ABBVIE INC. (US) 2015-08-04 US disclosed
US-20150191437-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS ABBVIE INC. (US) 2015-07-09 US disclosed
US-20150150870-A1 METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS ABBVIE INC. 2015-06-04 US disclosed
US-8980643-B2 Dicationic liquid salts and methods of use thereof SIGMA-ALDRICH CO., LLC (US) 2015-03-17 US disclosed
US-20140171429-A1 BICYCLIC INHIBITORS OF ALK ABBVIE INC. (US) 2014-06-19 US disclosed
EP-2105787-B1 DISPLAY ELEMENT AND DRIVING METHOD THEREOF KONICA MINOLTA HOLDINGS INC (JP) 2013-12-25 EP disclosed
US-8435980-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2013-05-07 US disclosed
US-8426408-B2 Pyrimidine inhibitors of kinases ABBVIE INC. (US) 2013-04-23 US disclosed
US-20120122924-A1 NAMPT INHIBITORS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-8064119-B2 Display element and driving method thereof KONICA MINOLTA HOLDINGS, INC. (JP) 2011-11-22 US disclosed
US-20110058244-A1 ELECTROCHROMIC DISPLAY ELEMENT KONICA MINOLTA HOLDINGS, INC. (JP) 2011-03-10 US disclosed
US-20110017908-A1 DICATIONIC LIQUID SALTS AND METHODS OF USE THEREOF SIGMA-ALDRICH CO. (US) 2011-01-27 US disclosed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US disclosed
US-20100091352-A1 DISPLAY ELEMENT AND DRIVING METHOD THEREOF KONICA MINOLTA HOLDINGS, INC. (JP) 2010-04-15 US disclosed
EP-2105787-A1 DISPLAY ELEMENT AND METHOD FOR DRIVING DISPLAY ELEMENT Konica Minolta Holdings, Inc. (JP) 2009-09-30 EP disclosed